Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9360098 | 0.82 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL548599 | 0.82 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL1107981 | 0.80 | ALDH1A1 (0.64) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL2739639 | 0.78 | ALDH1A1 (0.75) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL283836 | 0.78 | CA2 (0.70) | ALDH1A1KMT2AMEN1NPSR1CA1 | |
| SCHEMBL24411742 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL11613330 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL22518678 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL11738165 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1GAAKMT2A | |
| SCHEMBL196750 | 0.78 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110994-A1 | A PROCESS FOR THE PREPARATION OF LEDIPASVIR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-05-30 | — | — | WO | claimed |
| EP-3841101-B1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AG (DE) | 2023-05-03 | — | — | EP | claimed |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2023-02-23 | — | — | US | claimed |
| EP-4099991-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | Laurus Labs Limited (IN) | 2022-12-14 | — | — | EP | claimed |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | claimed |
| WO-2021156811-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2021-08-12 | — | — | WO | claimed |
| EP-3841101-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | Bayer Aktiengesellschaft (DE) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039025-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | WO | claimed |
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2019-04-23 | — | — | US | claimed |
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2018-01-25 | — | — | US | claimed |
| EP-2321279-B1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | PIRAMAL IMAGING SA (CH) | 2014-07-02 | — | — | EP | claimed |
| US-20140012032-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2014-01-09 | — | — | US | claimed |
| WO-2012052556-A1 | NOVEL HALOALKOXYQUINAZOLINES, AND PREPARATION AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2012-04-26 | — | — | WO | claimed |
| EP-2388245-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Pharma AG (DE) | 2011-11-23 | — | — | EP | claimed |
| US-20110254522-A1 | STANDBY POWER SUPPLY CIRCUIT | HON HAI PRECISION INDUSTRY CO., LTD. (TW) | 2011-10-20 | — | — | US | claimed |
| EP-2374779-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Pharma Aktiengesellschaft (DE) | 2011-10-12 | — | — | EP | claimed |
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | claimed |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-16 | — | — | US | claimed |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Lantheus Biosciences Ltd. (GB) | 2009-07-30 | — | — | US | claimed |
| EP-2053033-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Schering Pharma AG (DE) | 2009-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ALDH1A1 2741/4885LMNA 1871/4885HSD11B1 2431/4885 |
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PMP22, MEN1, VHL | ALDH1A1 2741/4885LMNA 1871/4885HSD11B1 2431/4885 |
| US-20110200535-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | GABRA6, GABRA4, GABRA1 | ALDH1A1 798/4885LMNA 2748/4885HSD11B1 3002/4885 |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | CYP3A4, CYP4A11, CYP3A43 | ALDH1A1 553/4885LMNA 2938/4885HSD11B1 98/4885 |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ALDH1A1 2741/4885LMNA 1871/4885HSD11B1 2431/4885 |
| US-20100233086-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ALDH1A1 2741/4885LMNA 1871/4885HSD11B1 2431/4885 |
| US-20140012032-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | APP, APBA1, BACE1 | ALDH1A1 2534/4885LMNA 1240/4885HSD11B1 1082/4885 |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | CYP1B1, CYP4B1, CYP1A1 | ALDH1A1 432/4885LMNA 793/4885HSD11B1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.